Intellia Therapeutics (NTLA) Cash from Financing Activities (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Cash from Financing Activities data on file, last reported at $33.6 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities changed N/A year-over-year to $33.6 million in Q1 2026; TTM through Mar 2026 was $165.1 million, a 31.25% increase from a year earlier, with the FY2025 full-year figure at $131.5 million, down 29.21% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $33.6 million, up from $2.0 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for NTLA reached as high as $505.8 million in Q4 2022 and fell as low as $2.0 million in Q4 2025.
• Historically, Cash from Financing Activities has averaged $66.5 million across 5 years, with a median of $28.8 million in 2022.
• Across the five-year window, Cash from Financing Activities soared 22082.59% in 2022 and plunged 97.82% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at $505.8 million in 2022, then plunged by 78.95% to $106.5 million in 2023, then plunged by 97.82% to $2.3 million in 2024, then decreased by 14.67% to $2.0 million in 2025, then soared by 1597.98% to $33.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $33.6 million in Q1 2026, $2.0 million in Q4 2025, and $114.9 million in Q3 2025.